

**ANONDITA MEDICARE LIMITED**AN ISO 9001:2015 ISO 13485:2016 & CDSO CERTIFIED CO.  
Manufacturer of Condoms

November 25, 2025

To,  
The Manager,  
Listing Compliance Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai-400051

**Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Termination of Agreement by Monitoring Agency**

**Ref.: SEBI Master Circular: SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024**

**SYMBOL: ANONDITA**  
**ISIN: INE0VTV01012**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has received a termination notice dated **November 12, 2025** from its Monitoring Agency, **CARE Ratings Limited** ("CARE").

As per the termination notice, the Monitoring Agency Agreement dated **August 14, 2025**, executed for monitoring the utilisation of the IPO proceeds in accordance with the SEBI ICDR Regulations, has been terminated by CARE.

The termination of the aforesaid agreement does not have any material adverse impact on the operations or financial position of the Company. The Company will continue to ensure full compliance with the applicable SEBI regulations relating to monitoring and reporting the utilisation of issue proceeds, including filings with the Stock Exchange(s).

The details as required under Reg. 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, read with Schedule III and SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, are also enclosed herewith as **Annexure-A**.

Kindly take the above information on your record.

Thanking You.  
Yours faithfully,

**For ANONDITA MEDICARE LIMITED**

**Anupam Ghosh**  
**Managing Director**  
**DIN: - 02675517**  
**Address: - C-6, Near D M Residence, Sector-27,**  
**Gautam Buddha Nagar, Uttar Pradesh-201301**



UNIT



OFFICE



DIPPING AREA



TESTING AREA

**Annexure A****Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with Schedule III and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Particulars	Details
1	Name(s) of the parties with whom the agreement is entered	NA
2	Purpose of entering into the agreement	NA
3	Size of the agreement	NA
4	Shareholding, if any, in the entity with whom the agreement is executed	NA
5	Significant terms of the agreement (in brief)	NA
6	Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship	NA
7	Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length	NA
8	In case of issuance of shares to the parties, details of issue price, class of shares issued	NA
9	In case of loan agreements – details of lender/borrower, loan terms, security, etc.	NA
10	Any other disclosures related to such agreements, such as nominee director, conflict of interest, etc.	NA
11	In case of termination or amendment (if applicable)	CARE Ratings Limited issued a termination notice dated November 7, 2025, reaffirmed on November 12, 2025, citing breach of agreement due to non-submission of requisite information in a timely manner. Termination becomes effective December 07, 2025.
	A. name of parties to the agreement;	<b>Anondita Medicare Limited and CARE Ratings Limited.</b>
	B. nature of the agreement	Monitoring Agency Agreement for monitoring the utilisation of IPO proceeds in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.



UNIT



OFFICE



DIPPING AREA



TESTING AREA



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDS CO CERTIFIED CO.  
Manufacturer of Condoms

Sr. No.	Particulars	Details
	C. date of execution of the agreement	August 14, 2025
	D. details of amendment and impact thereof or reasons of termination and impact thereof.	<p>CARE Ratings Limited issued a termination notice dated November 7, 2025, subsequently reaffirmed on November 12, 2025, citing non-receipt of adequate and complete information in a timely manner, which constituted a breach of the terms of the Agreement as per Clause 9.3. Accordingly, CARE elected to terminate its services as Monitoring Agency.</p> <p><b>Impact of termination:</b></p> <p>The termination of the Monitoring Agency Agreement does not have any material adverse impact on the operations or financial position of the Company. The Company will appoint a new Monitoring Agency and continue to comply with SEBI requirements relating to the monitoring and reporting of utilisation of IPO proceeds.</p>



UNIT



OFFICE



DIPPING AREA



TESTING AREA